Adjuvant modulation of immune responses to tuberculosis subunit vaccines

被引:191
作者
Lindblad, EB
Elhay, MJ
Silva, R
Appelberg, R
Andersen, P
机构
[1] STATENS SERUM INST,TB RES UNIT,BACTERIAL VACCINE DEPT,DK-2300 COPENHAGEN S,DENMARK
[2] CTR CITOL EXPT,P-4150 OPORTO,PORTUGAL
关键词
D O I
10.1128/IAI.65.2.623-629.1997
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Mice were immunized with experimental subunit vaccines based on secreted antigens from Mycobacterium tuberculosis in a series of adjuvants, comprising incomplete Freund's adjuvant (IFA), dimethyl dioctadecyl ammoniumbromide (DDA), RIBI adjuvant, Quil-A saponin, and aluminum hydroxide, Immune responses induced by these vaccines were characterized by in vitro culture of primed cells, PCR analysis for cytokine mRNA, detection of specific immunoglobulin G isotypes induced, and monitoring of protective immunity to tuberculosis (TB), The study demonstrated marked differences in the immune responses induced by the different adjuvants and identified both IFA and DDA as efficient adjuvants for a TB subunit vaccine, Aluminum hydroxide, on the other hand, induced a Th2 response which increased the susceptibility of the animals to a subsequent TB challenge, DDA was further coadjuvanted with either the Th1-stimulating polymer poly(I-C) or the cytokines gamma interferon, interleukin 2 (IL-2), and IL-12. The addition of IL-12 was found to amplify a Th1 response in a dose-dependent manner and promoted a protective immune response against a virulent challenge, However, if the initial priming in the presence of IL-12 was followed by two booster injections of vaccine without IL-12, no improvement in long-term efficacy was found, This demonstrates the efficacy of DDA to promote an efficient immune response and suggests that IL-12 may accelerate this development, but not change the final outcome of a full vaccination regime.
引用
收藏
页码:623 / 629
页数:7
相关论文
共 45 条
[1]   T-CELL PROLIFERATIVE RESPONSE TO ANTIGENS SECRETED BY MYCOBACTERIUM-TUBERCULOSIS [J].
ANDERSEN, P ;
ASKGAARD, D ;
LJUNGQVIST, L ;
BENTZON, MW ;
HERON, I .
INFECTION AND IMMUNITY, 1991, 59 (04) :1558-1563
[3]   SPECIFICITY OF A PROTECTIVE MEMORY IMMUNE-RESPONSE AGAINST MYCOBACTERIUM-TUBERCULOSIS [J].
ANDERSEN, P ;
HERON, I .
INFECTION AND IMMUNITY, 1993, 61 (03) :844-851
[4]   PROTEINS RELEASED FROM MYCOBACTERIUM-TUBERCULOSIS DURING GROWTH [J].
ANDERSEN, P ;
ASKGAARD, D ;
LJUNGQVIST, L ;
BENNEDSEN, J ;
HERON, I .
INFECTION AND IMMUNITY, 1991, 59 (06) :1905-1910
[5]   ADJUVANTS - CURRENT STATUS, CLINICAL PERSPECTIVES AND FUTURE-PROSPECTS (REPRINTED FROM TRENDS IN PHARMACOLOGICAL SCIENCES, VOL 14, PG 174-178, 1993) [J].
AUDIBERT, FM ;
LISE, LD .
IMMUNOLOGY TODAY, 1993, 14 (06) :281-284
[6]   NATURAL IMMUNITY - A T-CELL-INDEPENDENT PATHWAY OF MACROPHAGE ACTIVATION, DEFINED IN THE SCID MOUSE [J].
BANCROFT, GJ ;
SCHREIBER, RD ;
UNANUE, ER .
IMMUNOLOGICAL REVIEWS, 1991, 124 :5-24
[7]   INACTIVATED INFLUENZA VACCINE EFFICACY - DIMINISHED ANTIGENICITY OF SPLIT-PRODUCT VACCINES IN MICE [J].
BARRY, DW ;
STATON, E ;
MAYNER, RE .
INFECTION AND IMMUNITY, 1974, 10 (06) :1329-1336
[8]  
Bloom Barry R., 1994, P531
[9]  
BOMFORD R, 1980, CLIN EXP IMMUNOL, V39, P435
[10]  
CASTRO AG, 1995, IMMUNOLOGY, V85, P556